2017-03-14,Otonomy Becomes Oversold (OTIC)
2017-03-02,Otonomy Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-28,Otonomy To Present At Cowen And Company Health Care Conference
2017-02-24,Otonomy To Report Fourth Quarter And Full Year 2016 Financial Results And Provide Corporate Update
2017-01-26,Otonomy Enters Oversold Territory (OTIC)
2017-01-19,Otonomy Initiates Patient Enrollment In Phase 2 Clinical Trial Of OTO-104 As Protectant Against Cisplatin-Induced Hearing Loss
2017-01-09,Otonomy Provides Corporate And Product Pipeline Update
2017-01-06,First Week of OTIC February 17th Options Trading
2017-01-05,Otonomy Announces Positive Top-Line Results From Phase 3 Clinical Trial Of OTIPRIO® In Patients With Acute Otitis Externa
2017-01-03,Otonomy To Present At The J.P. Morgan Healthcare Conference
2016-11-30,Otonomy Appoints Kathie M. Bishop, Ph.D., As Chief Scientific Officer
2016-11-22,Otonomy To Present At Piper Jaffray Healthcare Conference
2016-11-03,Otonomy Enters Oversold Territory (OTIC)
2016-11-03,Otonomy Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-02,Otonomy Announces Assignment Of J Code For OTIPRIO®
2016-10-27,Otonomy To Report Third Quarter 2016 Financial Results And Provide Corporate Update
2016-10-07,Otonomy Holds Investor And Analyst Day And Provides Corporate Update
2016-10-04,Otonomy Successfully Completes Phase 2 Clinical Trial Of OTIPRIO® In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
2016-09-29,Otonomy To Host Investor And Analyst Day On October 7, 2016
2016-09-15,Late Recovery Wave Lifts Market
2016-09-15,Otonomy Successfully Completes Open-Label Clinical Trial For OTIPRIO® in Patients With History Of Otitis Media Requiring Tympanostomy Tubes
2016-09-13,Otonomy Announces OTIPRIO® Data Presentation And Symposium At American Academy Of Otolaryngology - Head And Neck Surgery Foundation Annual Meeting
2016-09-01,Otonomy To Present At Baird Global Healthcare Conference
2016-08-04,Otonomy Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-01,Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial For OTO-104 In Meniere's Disease Patients
2016-07-28,Otonomy To Report Second Quarter 2016 Financial Results And Provide Corporate Update
2016-06-09,Otonomy Initiates Patient Enrollment In Single Phase 3 Clinical Trial Of OTIPRIO™ In Patients With Acute Otitis Externa
2016-05-20,Otonomy Announces Assignment Of C Code And Pass-Through Payment Status For OTIPRIO™
2016-05-16,Otonomy Announces OTIPRIO™ Data Presentation And Symposium At Combined Otolaryngology Spring Meetings
2016-05-13,Commit To Buy Otonomy At $10, Earn 27.5% Annualized Using Options
2016-05-09,Otonomy Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-05,Oversold Conditions For Otonomy (OTIC)
2016-05-05,Otonomy To Present At The Bank Of America Merrill Lynch Healthcare Conference
2016-04-18,Otonomy Announces Phase 3 Clinical Trial Plan For OTIPRIO™ In Otitis Externa Patients Based On Successful End-of-Phase 2 Review By FDA
2016-03-23,Otonomy Initiates Patient Enrollment In Second Phase 3 Clinical Trial Of OTO-104 In Meniere's Disease
2016-03-18,Otonomy Announces Publication Of OTIPRIO™ Phase 3 Clinical Trial Results In JAMA Otolaryngology
2016-03-07,Otonomy Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update
2016-03-03,Otonomy Initiates Phase 2 Clinical Trial Of OTIPRIO™ In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
2016-03-02,Otonomy Announces Commercial Availability Of OTIPRIO™
2016-02-29,Otonomy To Present At Cowen And Company Health Care Conference
2016-02-26,Otonomy To Report Fourth Quarter And Full Year 2015 Financial Results And Provide Corporate Update
2016-02-18,Otonomy Enters Oversold Territory
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-11,Commit To Buy Otonomy At $10, Earn 11.7% Annualized Using Options
2016-01-26,Otonomy Announces Publication Supporting Development Of OTO-104 As Protectant Against Cisplatin-Induced Hearing Loss
2016-01-12,Otonomy Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2016-01-08,Otonomy To Present At J.P. Morgan Healthcare Conference
2016-01-06,Otonomy Announces Pricing Of Public Offering Of Common Stock
2016-01-06,Otonomy is Now Oversold (OTIC)
2016-01-05,Otonomy Announces Proposed Public Offering Of Common Stock
2015-12-15,Otonomy Added To NASDAQ Biotechnology Index
2015-12-11,Otonomy Announces FDA Approval Of OTIPRIO(TM) For The Treatment Of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
2015-12-01,Otonomy Completes Enrollment In OTIPRIO(TM) Phase 2 Trial And Demonstrates Clinical Feasibility In Patients With Acute Otitis Externa
2015-11-24,Otonomy To Present At Piper Jaffray Healthcare Conference
2015-11-18,Otonomy Initiates Patient Enrollment In U.S. Phase 3 Clinical Trial Of OTO-104 In Meniere's Disease
2015-11-16,Otonomy Initiates Phase 1 Clinical Trial For Tinnitus Product Candidate, OTO-311
2015-11-10,Otonomy Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-03,Otonomy Initiates Open-Label Clinical Trial For OTIPRIO(TM) In Pediatric Patients With History Of Otitis Media Requiring Tympanostomy Tubes
2015-10-27,Commit To Purchase Otonomy At $20, Earn 21.1% Annualized Using Options
2015-10-07,Otonomy Holds Investor And Analyst Day And Provides Corporate Update
2015-10-05,Otonomy Receives FDA Clearance Of Investigational New Drug Application For Tinnitus Product Candidate, OTO-311
2015-09-30,Otonomy To Host Investor And Analyst Day On October 7, 2015
2015-09-24,Otonomy To Present Results For AuriPro(TM) Phase 3 And OTO-104 Phase 2b Clinical Trials At 2015 AAO-HNSF Annual Meeting
2015-09-09,Otonomy Announces Successful End-of-Phase 2 Meeting With The FDA For OTO-104 In Meniere's Disease
2015-09-01,Otonomy Appoints Ted Schroeder To Board Of Directors
2015-08-12,Otonomy Reports Second Quarter 2015 Financial Results And Provides Corporate Update
2015-07-28,Commit To Purchase Otonomy At $25, Earn 15.6% Annualized Using Options
2015-07-28,Otonomy Initiates Phase 2 Clinical Trial For AuriPro(TM) In Second Label Expansion Indication
2015-07-17,5 Health Care Stocks Ready for Breakouts
2015-06-25,Relative Strength Alert For Otonomy
2015-06-02,Otonomy Enters Oversold Territory (OTIC)
2015-05-21,Otonomy Reports Phase 2b Topline Data For OTO-104 In Meniere's Disease
2015-05-18,Otonomy Appoints Eric Loumeau As General Counsel And Chief Compliance Officer
2015-05-12,Otonomy Reports First Quarter 2015 Financial Results And Provides Corporate Update
2015-05-07,Otonomy Completes Enrollment In Phase 2 Clinical Trial For AuriPro(TM) In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
2015-05-06,Otonomy To Present At Two Upcoming Investor Conferences
2015-04-30,Otonomy Appoints George Morrow To Board Of Directors
2015-04-28,Otonomy Announces FDA Acceptance Of AuriPro(TM) New Drug Application
2015-04-27,Otonomy Presents AuriPro(TM) Phase 3 Results At American Society Of Pediatric Otolaryngology Conference
2015-04-21,Otonomy To Present AuriPro(TM) Phase 3 Results At American Society Of Pediatric Otolaryngology Conference
2015-04-20,Otonomy Completes Enrollment Of OTO-104 Multiple-Dose Safety Study In Meniere's Disease Patients
2015-04-01,Otonomy Appoints Dean Hakanson, M.D., As Chief Medical Officer
2015-03-26,Otonomy Initiates Phase 2 Clinical Trial For AuriPro(TM) In Label Expansion Indication
2015-03-18,Otonomy Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update
2015-03-12,Otonomy To Report Fourth Quarter And Full Year 2014 Financial Results And Provide Corporate Update
2015-02-26,Otonomy Submits New Drug Application To The FDA For AuriPro(TM)
2015-02-24,Otonomy To Present At Two Upcoming Investor Conferences
2015-01-28,Otonomy Announces Closing Of Follow-on Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-01-22,Otonomy Announces Pricing Of Follow-on Public Offering
2015-01-21,Otonomy Announces Launch Of Follow-on Public Offering
2015-01-08,Otonomy Files Registration Statement For Proposed Follow-on Public Offering
2015-01-08,Otonomy Provides Corporate And Product Pipeline Update
2015-01-06,Otonomy To Present At The J.P. Morgan Healthcare Conference
2014-12-01,Otonomy Achieves Patient Enrollment Target In Phase 2b Clinical Trial Of OTO-104 In Meniere's Disease
2014-11-20,Otonomy To Present At The Piper Jaffray Healthcare Conference
2014-11-12,Otonomy Reports Third Quarter 2014 Financial Results And Provides Corporate Update
2014-11-06,Otonomy Obtains Rights To Gacyclidine Data From Ipsen To Support Development Of OTO-311 As A Treatment For Tinnitus
2014-10-21,Otonomy Appoints Anthony J. Yost Chief Commercial Officer
2014-10-09,Otonomy Enrolls First Meniere's Disease Patients In OTO-104 Multiple-Dose Safety Study
2014-10-01,Otonomy Added To Russell 2000(R) Index
2014-09-03,Otonomy Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares
2014-08-13,RiverVest Venture Partners’ Otonomy Completes $100 Million Initial Public Offering
2014-08-13,Otonomy Announces Pricing Of Initial Public Offering
,
,
